Dr. Reuben S. Harris on APOBEC3B as a Possible Treatment Variable in Breast Cancer
APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Reuben S. Harris, PhD, investigator, Howard Hughes Medical Institute, professor, Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, discusses the need for further analysis of APOBEC3B, an anti-viral enzyme, as a possible treatment variable in breast cancer.
APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Harris looked at APOBEC3B expression and stratified data for recurrent disease outcome overtime. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
